You are here
- Home
- Therapy Areas
Cardiovascular
The following trials provide information to treat various types of cardiovascular diseases, both for ongoing and completed clinical trials. For more information on this therapy area please click here.
- collapse A PK study of NXY-059 in renal impaired subjects
- collapse Safety and tolerability in patients with stroke
- collapse Evaluation of Target Organs Damage in Hypertensive Patients With no Known Cardiovascular (CV) or Renal Disease, Stratified According to Level of Blood Pressure Control
- collapse A Phase I, Single Centre, Open Study to Assess the Pharmacokinetics of oral AZD6140 after Single Dose in Healthy Japanese Male Volunteers
- collapse A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine
- collapse A 4-month treatment, Randomized, Double-blind, Placebo-Controlled, Multi-centre, Parallel-Group Phase 2 study to Evaluate Efficacy, Safety and Tolerability of Different Dosing Regimens of AZD1656 as Monotherapy in Japanese Type 2 Diabetes Mellitus Patients
- collapse A 4-month, Randomized, Double-blind, Placebo- and Active-Controlled, Multi-centre, Parallel-Group study, with an optional 2-month extension, to Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus Patients
- collapse A double blind, double dummy, phase IV, randomized, multicenter, parallel group, placebo control trial to evaluate the effect of rosuvastatin on triglycerides levels in Mexican hypertriglyceridemic patients.
- collapse A non interventional, cross sectional, retrospective, epidemiological study on the management of dyslipidemia in Type 2 DM adult patients in India
- collapse A Non Interventional, Cross Sectional, Study on the Prevalence of Sympathetic Overactivity in Hypertensive Patients.
